Etanercept Treatment in Ankylosing Spondylitis Hip Lesions / 대한고관절학회지

PURPOSE: To evaluate the efficacy of etanercept in patients with an ankylosing spondylitis hip lesion. MATERIALS AND METHODS: Between March 2008 and December 2011, this study evaluated 13 patients with hip lesions who were refractory to conventional therapy. The general improvement was evaluated by the Harris hip score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), ESR, CRP, and complications. RESULTS: The mean Harris hip score changed from 55.6+/-3.4 to 87.2+/-4.3(P=0.01). The mean BASDAI/ BASFI decreased from 6.8+/-1.7/6.8+/-1.6 before treatment to 4.4+/-1.8(P=0.02)/4.3+/-1.1(P=0.02) after treatment. The mean ESR/CRP changed from 48.4+/-31.5/5.8+/-5.1 to 20.8+/-19.7(P=0.06)/3.1+/-4.2(P=0.03). No complications were encountered. CONCLUSION: These results suggest that etanercept can induce significant pain improvement in most ankylosing spondylitis hip lesions.

A multi-factor analysis on the prevalence of lesion of hip joint in patients with ankylosing spondylitis / 中华风湿病学杂志

Objective To analyze the multiple factors for ankylosing spondylitis(AS)patients developing hip joint disease. Methods One hundred and two patients with AS complicated with hip joint damage (group A)were compared with 54 patients with AS without hip joint disease(group B). A univariate and multivariate unconditional-Logistic regression analysis was carried. Results The mean age at the time of disease onset was(17±8)years old in group A and(24±7)years in group B(P＜0.05). The course of disease onset was(5±4)years old in group A and(11±5)years in group B(P＜0.05). The childhood of disease onset was 37.3% in group A and 20.4% in group B(P＜0.05). The patients who had hip pain at the disease onset was 38.2% in group A and 25.9% in group B(P＜0.05).The incidence of peripheral arthritis was 39.2% and 20.4%(P＜0.05)in patients of group A and group B respectively. Laboratory and X-ray findings showed that ESR, CRP, IgG and IgM levels were higher in group A than those in group B. SASP and thalidomide dosage taken in group A was lower than that in group B(P＜0.01), the dosage of prednisone taken was higher in group A than in group B. A multivariate unconditional logistic regression analysis showed 5 factors, including the younger age of the time of disease onset, the short disease duration, the childhood of disease onset and hip joint involvement at the onset were associated with the occurrence of hip joint involvement. Conclusion The younger age, childhood and hip joint involvement at the time of disease onset, short disease duration may be the risk factors and SASP may be the protecting factor for patients developing hip joint lesion. More cases and factors analysis may be helpful to predict hip joint lesion in AS and to reduce the prevalence of disability.